{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:18:18Z","timestamp":1792732698715,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejps.2025.107182","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T11:37:23Z","timestamp":1750765043000},"page":"107182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["The impact of lipid compositions on siRNA and mRNA lipid nanoparticle performance for pulmonary delivery"],"prefix":"10.1016","volume":"212","author":[{"given":"Stina","family":"Rademacker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pinto Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcge","family":"Molbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Forn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Imhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Wibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heidecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"H\u00f6lig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-3916","authenticated-orcid":false,"given":"Olivia M.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejps.2025.107182_bib0001","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejps.2025.107182_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejps.2025.107182_bib0003","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"6","key":"10.1016\/j.ejps.2025.107182_bib0004","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S2213-2600(20)30157-0","article-title":"Chronic respiratory diseases: a global view","volume":"8","author":"Labaki","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"10","key":"10.1016\/j.ejps.2025.107182_bib0005","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41587-020-0692-z","article-title":"Mist begins to clear for lung delivery of RNA","volume":"38","author":"Shaffer","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.ejps.2025.107182_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4155\/tde-2019-0009","article-title":"Pulmonary delivery of siRNA as a novel treatment for lung diseases","volume":"10","author":"Kandil","year":"2019","journal-title":"Ther. Deliv."},{"issue":"18","key":"10.1016\/j.ejps.2025.107182_bib0007","article-title":"Exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions","volume":"13","author":"Tafech","year":"2024","journal-title":"Adv Heal. Mater."},{"key":"10.1016\/j.ejps.2025.107182_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"45","key":"10.1016\/j.ejps.2025.107182_bib0009","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"issue":"11","key":"10.1016\/j.ejps.2025.107182_bib0010","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"issue":"4","key":"10.1016\/j.ejps.2025.107182_bib0011","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.nano.2016.12.014","article-title":"Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA","volume":"13","author":"Kulkarni","year":"2017","journal-title":"Nanomedicine"},{"issue":"4","key":"10.1016\/j.ejps.2025.107182_bib0012","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1039\/D0BM01609H","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ejps.2025.107182_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119792","article-title":"PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production","volume":"588","author":"Suzuki","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"36","key":"10.1016\/j.ejps.2025.107182_bib0014","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Engl."},{"key":"10.1016\/j.ejps.2025.107182_bib0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jconrel.2022.03.051","article-title":"Inhibition of SARS-CoV-2 replication in the lung with siRNA\/VIPER polyplexes","volume":"345","author":"Baldassi","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejps.2025.107182_bib0016","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-0716-3918-4_14","article-title":"Fluorescent techniques for RNA detection in nanoparticles","volume":"2822","author":"Carneiro","year":"2024","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejps.2025.107182_bib0017","series-title":"Characterization of Nanoparticles Intended For Drug Delivery","first-page":"63","article-title":"Zeta potential measurement","author":"Clogston","year":"2011"},{"issue":"1","key":"10.1016\/j.ejps.2025.107182_bib0018","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41467-024-45666-5","article-title":"Liquid crystalline inverted lipid phases encapsulating siRNA enhance lipid nanoparticle mediated transfection","volume":"15","author":"Pattipeiluhu","year":"2024","journal-title":"Nat. Commun."},{"issue":"34","key":"10.1016\/j.ejps.2025.107182_bib0019","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew Chem. Int. Engl."},{"key":"10.1016\/j.ejps.2025.107182_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115065","article-title":"In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacy","volume":"165","author":"Escalona-Rayo","year":"2023","journal-title":"Biomed. PharmacOther"},{"key":"10.1016\/j.ejps.2025.107182_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100424","article-title":"Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs","volume":"41","author":"Suzuki","year":"2021","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejps.2025.107182_bib0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2013.05.040","article-title":"Mucus as a barrier to lipophilic drugs","volume":"453","author":"Sigurdsson","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejps.2025.107182_bib0023","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1038\/s41467-019-11593-z","article-title":"Brain-targeted drug delivery by manipulating protein corona functions","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ejps.2025.107182_bib0024","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1021\/acs.bioconjchem.3c00329","article-title":"Protein corona formation on lipid nanoparticles negatively affects the NLRP3 inflammasome activation","volume":"34","author":"Debnath","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.ejps.2025.107182_bib0025","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1039\/C6RA25493D","article-title":"In vivo protein corona patterns of lipid nanoparticles","volume":"7","author":"Amici","year":"2017","journal-title":"RSC. Adv."},{"key":"10.1016\/j.ejps.2025.107182_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123257","article-title":"Protein corona investigations of polyplexes with varying hydrophobicity - from method development to in vitro studies","volume":"643","author":"Hartl","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2025.107182_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107182_bib0028","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2023.01.014","article-title":"Targeted GATA3 knockdown in activated T cells via pulmonary siRNA delivery as novel therapy for allergic asthma","volume":"354","author":"Kandil","year":"2023","journal-title":"J. Control Release"},{"issue":"4","key":"10.1016\/j.ejps.2025.107182_bib0029","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1021\/acs.biomac.6b00164","article-title":"Size-limited penetration of nanoparticles into porcine Respiratory mucus after aerosol deposition","volume":"17","author":"Murgia","year":"2016","journal-title":"Biomacromolecules"},{"issue":"5","key":"10.1016\/j.ejps.2025.107182_bib0030","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/17425247.2021.1854222","article-title":"Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung","volume":"18","author":"Chen","year":"2021","journal-title":"Expert. Opin. Drug Deliv."},{"issue":"11","key":"10.1016\/j.ejps.2025.107182_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14112357","article-title":"Stability study of mRNA-lipid nanoparticles exposed to various conditions based on the evaluation between physicochemical properties and their relation with protein expression ability","volume":"14","author":"Kamiya","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.ejps.2025.107182_bib0032","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0005-2736(95)80016-9","article-title":"The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer","volume":"1235","author":"Farhood","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.ejps.2025.107182_bib0033","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1038\/s41467-019-12275-6","article-title":"Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells","volume":"10","author":"Maugeri","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.ejps.2025.107182_bib0034","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.ejps.2025.107182_bib0035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020597","article-title":"Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method","volume":"15","author":"Berger","year":"2023","journal-title":"Pharmaceutics"},{"issue":"18","key":"10.1016\/j.ejps.2025.107182_bib0036","article-title":"Exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions","volume":"13","author":"Tafech","year":"2024","journal-title":"Adv Heal. Mater."},{"issue":"1","key":"10.1016\/j.ejps.2025.107182_bib0037","article-title":"Elucidation of lipid nanoparticle surface structure in mRNA vaccines","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ejps.2025.107182_bib0038","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0005-2736(98)00077-7","article-title":"Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine","volume":"1372","author":"Webb","year":"1998","journal-title":"Biochim. Biophys. Acta - Biomembr."},{"issue":"6","key":"10.1016\/j.ejps.2025.107182_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199319","article-title":"New insights into the mechanisms controlling the bronchial mucus balance","volume":"13","author":"Karamaoun","year":"2018","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.ejps.2025.107182_bib0040","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1038\/s41598-021-86037-0","article-title":"Long-term evolution of the epithelial cell secretome in preclinical 3D models of the human bronchial epithelium","volume":"11","author":"Sanchez-Guzman","year":"2021","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ejps.2025.107182_bib0041","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.ejps.2025.107182_bib0042","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1039\/D0BM01609H","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2025.107182_bib0043","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrm2328","article-title":"Membrane recognition by phospholipid-binding domains","volume":"9","author":"Lemmon","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejps.2025.107182_bib0044","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/852430","article-title":"Annexin A2 at the interface of actin and membrane dynamics: a focus on its roles in endocytosis and cell polarization","volume":"2012","author":"Grieve","year":"2012","journal-title":"Int. J. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejps.2025.107182_bib0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4049\/jimmunol.1601263","article-title":"Surface LAMP-2 is an endocytic receptor that diverts antigen internalized by Human dendritic cells into highly immunogenic exosomes","volume":"199","author":"Leone","year":"2017","journal-title":"J. Immunol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T10:13:50Z","timestamp":1757844830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725001812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":45,"alternative-id":["S0928098725001812"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107182","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of lipid compositions on siRNA and mRNA lipid nanoparticle performance for pulmonary delivery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107182"}}